Vivalink Releases Biometrics Data Platform 2.0, Increasing Remote Patient Monitoring Patient Adherence

New updates address common industry challenges for RPM patient adherence in clinical trials and healthcare

Vivalink, a leading provider of digital healthcare solutions, has released an updated version of its Biometrics Data Platform with new features aimed at increasing patient adherence in Remote Patient Monitoring (RPM).

Vivalink’s Biometrics Data Platform accelerates the implementation and time-to-market of remote patient monitoring for healthcare and clinical trials by combining a turn-key end-to-end solution consisting of a suite of wearable sensors, edge-to-cloud integration, and advanced data  management and analytics both in real-time and retrospectively. The software platform is designed for flexible interoperability with mobile and web enabled clinical applications, electronic health record (EHR) systems and clinical trial management systems (CTMS).

While the adoption of RPM has accelerated with the pandemic and is expected to grow exponentially, patient adherence remains a top challenge. In a Decentralized Clinical Trial (DCT) survey by Vivalink, 69 percent of respondents indicated ‘patient adherence’ as the top concern.

To address this concern, the new Biometrics Data Platform updates include:

  • Data Integrity Assurance – notification of interruptions in data capture
  • New Adhesives Options – designed for sensitive skin and facilitates extended wear times
  • Sensor Status Indicators – detects when sensors are not connected or have become disconnected
  • Central Operational Console – systems management view of distributed patient sensors and data capture status across multiple locations to ensure proper adherence
  • Data Management Portal – A multi-functional web portal for patient/participant management, vital data visualization, analysis, and notifications based on advanced algorithms

Vivalink takes a “patient centric” approach to its RPM solution, which includes making its devices as easy to use and comfortable as possible for the patient. For example, its medical grade multi-vital cardiac patch is among the world’s smallest and lightest, weighing just 7.5 grams, increasing comfort while reducing disruption to daily routines.

“As a technology solution provider, we strive for the most advanced and effective solutions for remote patient monitoring,” said Jiang Li, CEO of Vivalink. “Patient adherence is a major bottleneck for the wider adoption of RPM. Today’s release of these features focusing on improving patient adherence shows our firm commitment to the patient-centric approach of our solution.

”More than 150 digital healthcare solution partners and commercial customers in 41 countries are delivering a wide range of medical applications using Vivalink’s Biometrics Data Platform. Vivalink’s solution is the basis of clinical research studies at leading institutions, including a 3,000 patient atrial fibrillation study at UCSF and a study of the effects of stress and teenage depression at Stanford University. Most recently, the platform has been adopted by health technology companies developing AI solutions, algorithm development and validation. The platform meets high levels of global compliance, including HIPAA, GDPR, FDA 21 CFR Part 11, ISO 13485, IEC 62304, ISO 14971, ISO 10993, and ISO 27001.

For more information, visit www.vivalink.com.

SourceVivalink

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version